New Marketing Authorisation Application submitted to EMA for Ibrutinib for the treatment of two forms of blood cancer
“The EMA Marketing Authorisation Application is an important milestone in…
30 October 2013 | By Johnson & Johnson
“The EMA Marketing Authorisation Application is an important milestone in the development of ibrutinib...”